IV Glutathione Therapy: Clinical Uses, Dosing Protocols, and What to Expect

At a Glance

Glutathione (GSH) is the most abundant intracellular antioxidant in the human body, present in virtually every cell at millimolar concentrations. It drives phase II hepatic detoxification, quenches reactive oxygen species (ROS), regenerates vitamins C and E, and regulates immune signaling through redox-sensitive transcription factors including NF-κB. When glutathione stores are depleted — as occurs predictably in chronic infection, heavy-metal burden, mitochondrial dysfunction, and aging — the consequences cascade across nearly every organ system.

The challenge is delivery. Oral glutathione is cleaved by intestinal peptidases and enteric bacteria, resulting in systemic bioavailability well below 10% for most commercial formulations. Liposomal encapsulation improves this modestly, but intravenous administration remains the gold standard for rapidly restoring tissue glutathione levels. This guide covers the clinical evidence, dosing logic, practical protocols, and patient selection criteria I use at my practice.

Why Glutathione Drops — and Why It Matters

Cellular glutathione declines with age, but this decline is dramatically accelerated by the conditions I see most often in complex chronic illness:

Heavy-metal burden: Lead, mercury, arsenic, and cadmium bind directly to the thiol group of glutathione, consuming it at an accelerated rate. Hair analysis and urine porphyrin patterns frequently reveal low GSH status in patients with documented heavy-metal accumulation.

Chronic infection and immune activation: Persistent infections — Lyme disease, Bartonella, reactivated Epstein-Barr, post-COVID microclot syndrome — generate sustained cytokine-driven ROS. The immune system’s oxidative burst is essential for pathogen clearance, but ongoing inflammation depletes glutathione faster than biosynthesis can replenish it.

Mitochondrial dysfunction: GSH is required for mitochondrial membrane integrity and for protecting mtDNA from oxidative damage. Mitochondria contain their own GSH pool, separate from cytosolic stores, and this compartment is particularly vulnerable in CFS/ME and post-viral fatigue states.

Liver toxicity: Hepatocytes depend on glutathione for phase II conjugation of xenobiotics. In non-alcoholic fatty liver disease (NAFLD), alcoholic hepatitis, and drug-induced liver injury, hepatic GSH is severely depleted — precisely when protection is needed most.

Clinical Evidence: Where the Data Is Strongest

Parkinson’s Disease

The most compelling IV glutathione data comes from neurological research. A 2009 pilot RCT by Mischley et al. demonstrated that intranasal GSH improved motor symptoms in early Parkinson’s patients over a 3-month period. Earlier open-label work by Sechi et al. (1996) showed significant symptom improvement with IV glutathione 600 mg twice daily. The mechanism is likely dual: dopaminergic neurons are exquisitely sensitive to oxidative stress, and glutathione may also facilitate clearance of misfolded alpha-synuclein via the ubiquitin-proteasome system.

Cisplatin-Induced Peripheral Neuropathy

A multicenter Italian RCT (Cascinu et al., 1995; n=52) found IV glutathione 1,500 mg/m² significantly reduced the incidence and severity of cisplatin-induced neuropathy compared to placebo. This is now a recognized supportive care application in integrative oncology, though timing relative to chemotherapy infusion matters — GSH should not be given within 2 hours of platinum-based agents.

Liver Disease and Fibrosis

A 2017 randomized trial published in Medicine (Choi et al.) found that IV glutathione 1,200 mg/day for 4 months significantly reduced ALT, AST, and markers of oxidative stress in patients with NAFLD. Separate Italian data support IV GSH for alcoholic hepatitis and cirrhosis-associated enzyme elevation.

Heavy-Metal Facilitation

While glutathione is not a licensed chelation agent in the same category as EDTA or DMSA, it plays a mechanistic role in facilitating mercury methylation status and supporting renal excretion of certain toxic metals. In my clinical practice, IV glutathione is frequently layered into heavy-metal protocols alongside established chelators, administered on alternating days to support antioxidant recovery between chelation sessions.

Dosing Protocols I Use Clinically

Dosing is guided by clinical indication, baseline GSH status (measured via red-blood-cell glutathione or urinary 8-OHdG as a proxy for oxidative burden), and patient tolerance.

Standard Antioxidant / Maintenance Protocol

• Dose: 600–1,000 mg IV push over 10–15 minutes
• Frequency: Weekly
• Dilution: In 10–20 mL sterile saline
• Use case: Longevity maintenance, mild fatigue, post-illness recovery

Liver Support / Detoxification Protocol

• Dose: 1,200–1,800 mg IV drip over 45 minutes
• Frequency: 2–3× per week for 4–6 weeks, then weekly
• Adjuncts: Alpha-lipoic acid 300–600 mg, B-complex, magnesium
• Use case: NAFLD, drug-induced hepatotoxicity, heavy-metal clearance support

Neurological / Post-COVID Protocol

• Dose: 1,500–2,400 mg IV drip over 60 minutes
• Frequency: 3× per week for 3–4 weeks
• Adjuncts: NAD+ IV, phosphatidylcholine, B12 high-dose
• Use case: Brain fog, post-COVID microclot sequelae, Parkinson’s support

Skin Brightening Protocol

• Dose: 600–1,200 mg weekly
• Duration: 8–12 weeks
• Note: Melanin suppression occurs via inhibition of tyrosinase enzyme; this is a documented effect but secondary to the primary antioxidant rationale in my practice

Rate of administration matters: Rapid IV push (< 5 minutes) increases the risk of vasodilation, sulfur odor, and transient chest tightness. I prefer slow push over 15 minutes for doses above 1,000 mg. Doses above 2,000 mg should routinely be given as a 60-minute drip.

Oral vs. Liposomal vs. IV: A Practical Comparison

For patients with complex chronic illness, oral forms are adjuncts, not replacements. I use liposomal GSH 500 mg twice daily between IV sessions to sustain tissue levels, combined with N-acetylcysteine (NAC) 600–1,200 mg daily as a glutathione precursor that has superior oral bioavailability.

Supporting and Recycling Glutathione

IV glutathione works better and lasts longer when cofactors for endogenous synthesis and recycling are adequate:

• N-Acetylcysteine (NAC): Donates cysteine, the rate-limiting amino acid for glutathione synthesis. 600–1,800 mg/day orally.
• Alpha-Lipoic Acid (ALA): Regenerates oxidized glutathione back to the reduced (active) form. 300–600 mg/day. Also given IV in our heavy-metal protocols.
• Selenium: Required cofactor for glutathione peroxidase (GPx), the enzyme that uses GSH to neutralize hydrogen peroxide. 100–200 mcg/day.
• Riboflavin (B2): Required for glutathione reductase, the enzyme that recycles GSSG → GSH. Often depleted in mitochondrial dysfunction.
• Magnesium: Cofactor for glutathione synthetase and multiple mitochondrial enzymes.
• Vitamin C: Spares glutathione by handling ascorbate-reducible ROS, freeing GSH for heavier oxidants. IV vitamin C and IV glutathione are complementary and often co-administered.

Monitoring and Safety Considerations

IV glutathione is generally well-tolerated, but practitioners should be aware of several practical points:

Sulfur sensitivity: Patients with significant sulfur sensitivity (common in certain methylation variants and in some mold-illness presentations) may react to glutathione’s thiol group with paradoxical fatigue or flu-like symptoms. Starting with low doses (300–600 mg) and titrating up is prudent in these individuals.

Concurrent chemotherapy: Glutathione may theoretically reduce cisplatin efficacy if given within the therapeutic window. The evidence is mixed, but oncology coordination is mandatory before using IV GSH in active cancer treatment.

Bronchospasm risk (nebulized form): Nebulized glutathione for lung conditions carries a small risk of bronchospasm, particularly in asthmatic patients. A trial dose with bronchodilator on hand is advisable.

Lab monitoring I use: RBC glutathione (baseline, then 6-week recheck), comprehensive metabolic panel, urinary 8-OHdG, and plasma cysteine in patients with suspected metabolic block.

What Patients Can Expect

Most patients notice something within the first 1–3 sessions. The earliest effect is typically improved mental clarity — patients describe it as “the fog lifting” — followed by improved energy and reduction in muscle aching. Skin changes (increased luminosity) become apparent after 4–8 sessions in patients receiving doses above 1,000 mg.

In complex chronic illness, I counsel patients that IV glutathione is part of a system, not a standalone intervention. When GSH stores are restored, the body becomes more capable of processing and excreting the backlog of toxins that have accumulated. This can occasionally produce a transient worsening — a detox response — particularly in heavy-metal-burdened patients. Adequate hydration and molybdenum supplementation can help mitigate this.

Sessions take 15–60 minutes depending on dose and infusion rate. Patients typically leave feeling calm and clear. The effect can feel energizing or relaxing depending on the individual’s baseline oxidative state.

Related Articles

• IV Laser Therapy: Mechanism, Evidence, and Clinical Applications
• Heavy Metal Chelation Protocols: EDTA, DMSA, and DMPS Compared
• NAC vs. Glutathione: Which Should You Take?
• Ozone Therapy: Evidence, Risks, and Protocols
• Alpha-Lipoic Acid: Clinical Uses and Dosing

References

1. Choi JH, et al. “Intravenous glutathione in patients with NAFLD: randomized clinical trial.” Medicine (Baltimore). 2017;96(47):e8430.
2. Cascinu S, et al. “Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy.” J Clin Oncol. 1995;13(1):26–32.
3. Sechi G, et al. “Reduced intravenous glutathione in the treatment of early Parkinson’s disease.” Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(7):1159–70.
4. Mischley LK, et al. “Phase IIb study of intranasal glutathione in Parkinson’s disease.” J Parkinsons Dis. 2017;7(2):289–299.
5. Exner R, et al. “Therapeutic potential of glutathione.” Wien Klin Wochenschr. 2000;112(14):610–6.
6. Leeuwenburgh C, Heinecke JW. “Oxidative stress and antioxidants in exercise.” Curr Med Chem. 2001;8(7):829–38.
7. Richie JP Jr, et al. “Randomized controlled trial of oral glutathione supplementation on body stores.” Eur J Nutr. 2015;54(2):251–63.